Maximus, Inc. (MMS) Stock Price & How to Invest

Last updated November 2026

Short answer

Maximus, Inc. (NYSE: MMS) is a Virginia-based government services contractor that runs Medicaid enrollment, ACA marketplace call centers, disability assessments and federal program operations for roughly $5.25 billion in trailing revenue. Shares trade on the NYSE and are available through any US brokerage, though at a ~$3.2 billion market cap (October 16, 2026, near $60.67 a share, down about 30% year to date) the stock carries a single-digit earnings multiple that says more about political risk than about the operating results.

MMS stock price

As of 2026-11-16, Maximus, Inc. (MMS) last closed at $65.40, down 16.5% over the past year. Over the past 52 weeks it has traded between $52.10 and $98.93.

MMS last close
$65.40
1 day
+1.07%
1 month
+6.39%
1 year
-16.54%
52-week range
$52.10 to $98.93
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Maximus, Inc.'s investor relations page. Walnut is informational, not investment advice.

MMS key stats

At $65.40 on November 16, 2026, Maximus, Inc. (MMS) has a market cap of $3.4B, a P/E of 9.7 on trailing earnings (7.8 on forward earnings) and a dividend yield of 2.02%. It next reports earnings on November 20, 2026.

Market cap
$3.4B
P/E (trailing)
9.7
P/E (forward)
7.8
EPS (trailing 12 months)
$6.76
Price to book
2.0
Dividend yield
2.02%
Beta
0.55
Next earnings
November 20, 2026

Market cap, P/E and yield are measured at the $65.40 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Maximus, Inc. (MMS)?

The last two weeks for Maximus, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • MMS closed at $65.40 on November 16, 2026, down 0.4% over the past five trading days (from $65.64).
  • Maximus, Inc. next reports quarterly results on November 20, 2026.

Maximus, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Maximus, Inc. (MMS) do?

Maximus is a tech-enabled services company whose customer is almost entirely the government. Its three segments are U.S. Federal Services (~$721 million of revenue in the June 2026 quarter), U.S. Services (~$418 million) and Outside the U.S. (~$140 million). Work spans call centers and eligibility processing for Medicaid, CHIP and the ACA marketplaces, medical disability examinations for the Department of Veterans Affairs, employment and welfare-to-work programs in the United Kingdom, and a growing block of automation and AI-enabled case handling. Federal agencies supplied roughly 55 percent of trailing revenue, state agencies roughly a third (New York alone is about 11 percent), and international governments about 11 percent. Just under 60 percent of revenue sits on performance-based contracts, which is where both the margin upside and the volume risk live.

The investment picture is unusually stark. Over the twelve months to June 2026 Maximus earned ~$371 million of net income on ~$5.25 billion of revenue, expanded operating margin, bought back stock and raised the dividend, yet as of October 16, 2026 the shares were down about 28 percent over the past year and about 30 percent year to date, changing hands near ~9 times trailing earnings and ~7.3 times forward estimates. They have bounced about 8.5 percent in the past month from a 52-week low near $51. Bears point at the customer concentration: a single directive from Washington or a state legislature can reprice a program overnight, as the temporary contract modification on a major federal program (guided at roughly $0.35 per share per quarter through the December 2026 period) demonstrated in August 2026. Bulls counter that revenue guidance was reiterated at $5.2 billion to $5.35 billion, free cash flow guidance sits at $425 million to $475 million, and a company converting that much of its profit to cash rarely trades at about 0.6 times sales for long. Which view is right depends on whether the current federal spending posture is a cycle or a regime change.

What's driving Maximus, Inc. (MMS)?

1. Margin expansion from automation, not from growth

Revenue has been flat to down, but operating margin moved from ~9.7 percent in fiscal 2025 to ~11.0 percent on a trailing basis, and third-quarter operating margin reached 12.6 percent. Management attributes the gain to efficiency programs and broader deployment of automation and AI-enabled tools across case handling. Because so much of the cost base is labor, each point of automation flows straight to segment income. In the June quarter adjusted EPS of $2.22 edged past the roughly $2.20 consensus, its third beat in four quarters after a narrow miss in the September 2025 quarter.

2. Federal Services carries the profit pool

U.S. Federal Services delivered an 18.6 percent segment operating margin in the June quarter, roughly double the U.S. Services segment and far above the international unit's 0.9 percent. Clinical work, principally the VA medical disability examination contracts, sits inside it, along with the $367.2 million of intangibles from a 2021 acquisition tied to those contracts. Fiscal 2026 segment margin is guided to 16.5 to 17 percent after the temporary contract modification.

3. A pipeline that dwarfs the revenue base

At June 30, 2026 the reported sales pipeline stood at ~$50.4 billion, with ~$2.86 billion of proposals pending and ~$2.42 billion in preparation. New work accounts for roughly 57 percent of it and federal opportunities for about 55 percent. Year-to-date signed awards of ~$1.25 billion and ~$1.35 billion of awarded-but-unsigned contracts are the near-term evidence of conversion; management has flagged SNAP-related offerings and defense and national security as the areas drawing interest.

4. Shrinking the share count while paying a dividend

Diluted shares fell from ~58.1 million to ~54.2 million over the past year, with 0.75 million shares repurchased for ~$50.4 million in the June quarter alone and a fresh $400 million authorization in place. The quarterly dividend rose to $0.33 and was declared again on October 5, 2026, a ~2.2 percent yield at the October price on a payout ratio near 19 percent. Gross debt of ~$1.73 billion against ~$57 million of cash means capital returns compete directly with deleveraging.

5. The November report and fiscal 2027 guidance

Maximus closes its fiscal year on September 30 and reports on November 19, 2026. Consensus calls for EPS near $1.85 on about $1.3 billion of revenue for the quarter, roughly $8.01 for fiscal 2026, and about $8.36 on $5.38 billion of revenue for fiscal 2027. The first fiscal 2027 outlook, and whether the federal contract modification ends on schedule at December 31, 2026, will set the tone for a stock trading on policy risk.

What are the risks to Maximus, Inc. (MMS)?

Customer concentration is the defining exposure: federal and state agencies supply essentially all revenue, and the August 2026 guidance cut came not from lost business but from a customer-directed contract modification on one major federal program worth about $0.35 per share per quarter. Program-level policy shifts affecting Medicaid, CHIP or the ACA marketplaces can move whole segments without any operational failure at Maximus. On the legal side, Maximus Federal Services is a defendant in consumer class actions arising from the 2023 MOVEit file-transfer breach, now centralized as a multidistrict litigation in the District of Massachusetts where the company was named a bellwether defendant; roughly half the claims against it survived a July 2025 motion to dismiss and are in discovery, a related Florida state action (Taylor v. Maximus Federal Services) is stayed, and an amount has been accrued. No pending securities-fraud class action is disclosed in the Legal Proceedings item of the latest 10-Q. Leverage is meaningful, with gross debt of ~$1.65 billion after a $325 million term loan upsize in May 2026, and the Outside the U.S. segment is only guided to break even for the full year. Analyst coverage is thin (two analysts in the Yahoo consensus, mean target about $92.50), so the share price can move sharply on a single contract or policy headline.

Is MMS a buy or a sell?

We give no verdict on Maximus, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Margin expansion from automation, not from growth. Revenue has been flat to down, but operating margin moved from ~9.7 percent in fiscal 2025 to ~11.0 percent on a trailing basis, and third-quarter operating margin reached 12.6 percent.

The case against. Customer concentration is the defining exposure: federal and state agencies supply essentially all revenue, and the August 2026 guidance cut came not from lost business but from a customer-directed contract modification on one major federal program worth about $0.35 per share per quarter.

Read the full bull and bear case on MMS, including what would have to change to break either one. Walnut is not an investment adviser.

Has Maximus, Inc. (MMS) split its stock?

No. Maximus, Inc. (MMS) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Maximus, Inc. (MMS) valued?

Market cap, P/E and dividend yield at today's price are in the MMS key stats above. The business figures below come from Maximus, Inc.'s reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$5.25B; June quarter down ~5% year over year
  • Net income (TTM): ~$371M (operating margin ~12.6%)
  • Free cash flow (TTM): ~$354M on Yahoo's basis; FY2026 guide $425M-475M

As of October 2026: Fiscal 2026 guidance calls for revenue of ~$5.2B to ~$5.35B, adjusted diluted EPS of ~$7.90 to ~$8.20, adjusted EBITDA margin near 13.7 percent and free cash flow of ~$425M to ~$475M. At roughly ~0.61 times sales and ~7 times EV/EBITDA as of October 16, 2026, after a 30 percent decline this year, the market is applying a valuation more typical of a declining business than of one guiding to record adjusted earnings. Reconciling those two requires a view on federal contracting policy rather than on the income statement.

Who competes with Maximus, Inc. (MMS)?

Federal services and IT primes

Leidos, Booz Allen Hamilton, CACI International, SAIC and ICF International bid against Maximus for federal program operations, modernization and advisory work. Most carry a heavier technology and defense mix; Maximus is weighted toward citizen-facing operations and clinical assessment, which is why its margins and its political sensitivity both differ from theirs.

Health and human services administrators

Conduent, Deloitte, Accenture Federal Services and Gainwell Technologies compete for state Medicaid, CHIP and eligibility contracts, often on multi-year procurements where incumbency matters more than price. Losing or winning a single large state can swing several percent of the U.S. Services segment, and New York alone accounts for roughly 11 percent of total revenue.

International assessment and employment providers

In the United Kingdom, Serco, Capita and Ingeus (Providence Service Corporation) bid for the same functional assessment and welfare-to-work programs that make up the Outside the U.S. segment. Contract structures there lean on outcome payments for job placement and retention, which produces the thin and volatile margins that segment has reported.

What stocks are similar to Maximus, Inc. (MMS)?

Other names that sit close to MMS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Maximus, Inc. (MMS)

There are three common ways to get MMS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so MMS sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where MMS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Maximus, Inc. (MMS)

Maximus is a profitable, cash-generative government outsourcer priced as if its federal and state contract base is about to shrink, and the gap between those two facts is the entire argument over the stock. Fiscal fourth-quarter results, due November 19, 2026, will show the first full quarter under the temporary federal contract modification and the company's first look at fiscal 2027.

More on Maximus, Inc. (MMS)

Whether MMS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MMS a buy or a sell?, and where the stock could go from here in the MMS stock forecast.

For income investors, whether MMS pays a dividend and how the payout looks is covered in does MMS pay a dividend? And to weigh MMS against a peer, read the full side-by-side comparisons: MMS vs LDOS and MMS vs BAH.

Wondering how MMS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Maximus, Inc.

Ask Walnut's AI anything about MMS and see how it fits what you own.

FAQ

What does Maximus actually do?

+

Maximus operates government programs under contract. Its people run Medicaid and CHIP enrollment centers, ACA marketplace support lines, medical disability examinations for the VA, employment services in the UK and Canada, and the technology behind those programs. Governments pay it to administer services rather than build them in-house.

Why is MMS trading at such a low P/E?

+

At roughly ~9 times trailing earnings and ~7.3 times forward estimates (October 2026), the multiple reflects who the customer is. Nearly all revenue comes from federal and state agencies, so investors are discounting the risk that budget or policy decisions shrink program volumes. Fiscal 2026 adjusted EPS guidance of ~$7.90 to ~$8.20 sits well above the trailing figure, which is why the forward multiple is lower still.

Does Maximus pay a dividend?

+

Yes. The board declared a quarterly dividend of $0.33 per share on July 6, 2026, payable August 31 to holders of record August 14, for an annualized $1.32. The board declared the same $0.33 again on October 5, 2026; at the October price the yield is near ~2.2 percent. Payout is around 20 percent of earnings, and the quarterly rate rose from $0.30 a year earlier.

What caused the August 2026 guidance change?

+

Maximus agreed to a temporary customer-directed contractual modification on a major federal program, effective July 1, 2026 through December 31, 2026. Management expects it to reduce diluted EPS by roughly $0.35 per quarter through that window. Revenue guidance was reiterated; only the earnings range moved, to ~$7.90 to ~$8.20 adjusted.

Is there active litigation against Maximus?

+

Consumer class actions stemming from the 2023 MOVEit file-transfer breach are pending against subsidiary Maximus Federal Services, centralized in a multidistrict litigation in the District of Massachusetts where the company is a bellwether defendant. About half the claims survived a July 2025 dismissal ruling and are in discovery. An amount has been accrued. No securities-fraud class action is disclosed.

How exposed is Maximus to federal spending cuts?

+

Heavily. U.S. federal agencies supplied roughly 55 percent of revenue in the nine months to June 2026 and the Federal Services segment carries the highest margin, near 18.6 percent last quarter. State agencies add roughly a third more. Very little revenue comes from commercial customers, so program-level decisions in Washington and state capitals drive results directly.

How do you buy MMS shares?

+

Maximus lists on the New York Stock Exchange under the ticker MMS, so any US brokerage that offers NYSE-listed equities can execute the order. Fiscal year ends September 30, and results are typically reported in November (fiscal 2026 fourth-quarter results are scheduled for November 19, 2026), February, May and August. Fractional shares are available at brokers that support them.

Is Maximus growing?

+

Revenue declined about 3.3 percent over the trailing twelve months to ~$5.25 billion, partly because the prior year included elevated natural disaster support work and temporary clinical volume surges. Earnings grew regardless, with EPS up around 25 percent on margin expansion and a shrinking share count. Growth in the reported figures currently comes from efficiency and buybacks rather than from new volume.

How did Maximus do in its latest quarter?

+

For the quarter ended June 30, 2026 (fiscal third quarter, reported in August), revenue was about $1.28 billion, down about 5 percent year over year, while net income rose to about $104 million and adjusted EPS of $2.22 beat the roughly $2.20 consensus. Operating margin reached 12.6 percent. The quarter also brought the temporary federal contract modification that lowered full-year EPS guidance to ~$7.90 to ~$8.20 adjusted.

How has MMS stock performed in 2026?

+

As of October 16, 2026, MMS closed near $60.67, down about 30 percent year to date and about 28 percent over one year, though up about 8.5 percent over the past month and 7 percent over three months. The 52-week range runs from about $51 to $100. Walnut is not an investment adviser; the figures describe past moves only.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Maximus, Inc.'s investor relations page or your broker before making investment decisions.